In an elderly patient with Alzheimer’s disease who is sleeping 12–14 hours per day and has poor oral intake, why is a positron emission tomography (PET) scan preferred over a computed tomography (CT) scan for assessing dementia severity and progression?

Why PET Scan is Preferred Over CT for Dementia Evaluation

PET imaging (both FDG-PET and amyloid PET) is vastly superior to CT for evaluating dementia severity and progression because it directly measures functional brain activity and pathological protein deposition, while CT only shows structural changes that occur much later in the disease process and provides limited diagnostic or prognostic information. 1

Key Advantages of PET Over CT

Superior Diagnostic Accuracy

• FDG-PET demonstrates sensitivity up to 96% and specificity up to 100% for discriminating AD from healthy patients, compared to CT which merely detects late-stage atrophy 1
• FDG-PET has greater accuracy than MRI and clinical criteria alone for diagnosing AD, showing characteristic hypometabolism in parietal/temporal lobes, precuneus, and posterior cingulate gyrus 1
• Amyloid PET has higher sensitivity than both brain MRI and FDG-PET for AD diagnosis, detecting pathology in >86% of patients with high specificity 1

Functional vs. Structural Information

The fundamental difference is what each modality measures:

PET imaging reveals:

• Active neuronal dysfunction and metabolic impairment (FDG-PET)
• Actual amyloid protein deposition in brain tissue (amyloid PET)
• Disease severity correlating with microscopic neuronal loss and gliosis 2

CT imaging only shows:

• Gross structural lesions (subdural hematomas, masses)
• Late-stage hippocampal and cortical atrophy
• No functional or metabolic information 1

Clinical Impact and Disease Staging

For your elderly patient with severe symptoms (sleeping 12-14 hours, poor oral intake):

PET provides critical information that CT cannot:

1. Confirms underlying pathology: Amyloid PET definitively establishes whether AD pathology is present, which is required before initiating antiamyloid monoclonal antibody therapy 1

2. Assesses disease severity: FDG-PET metabolic patterns correlate with dementia severity and predict clinical deterioration—patients with severely impaired metabolism have up to 4.7-times higher risk of deterioration 3

3. Distinguishes dementia types: PET differentiates AD from frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and vascular dementia based on metabolic patterns, while CT cannot make these distinctions 1

4. Prognostic value: Combined FDG-PET and amyloid PET achieve 97% sensitivity and 98% specificity for AD pathology; incongruent results suggest mixed dementia 1

When CT Has Limited Utility

CT's primary role is restricted to:

• Excluding treatable structural mimics (subdural hematoma, tumor, hydrocephalus)
• Initial screening when advanced imaging unavailable
• Patients who cannot undergo PET scanning

CT provides no information about:

• Disease progression rate
• Treatment eligibility (especially for new disease-modifying therapies)
• Differential diagnosis between dementia subtypes
• Functional reserve or metabolic activity

Practical Clinical Algorithm

For dementia evaluation, the imaging sequence should be:

1. Initial structural imaging (CT or preferably MRI) to exclude treatable structural lesions
2. FDG-PET for metabolic assessment, disease severity, and differential diagnosis
3. Amyloid PET when:
   • Treatment with disease-modifying therapy is considered
   • Diagnosis remains uncertain after FDG-PET
   • Atypical presentation or early-onset disease (<65 years)
   • Multiple potential causes of cognitive impairment 1

Important Caveats

Amyloid PET limitations:

• Can be positive in cognitively normal elderly (especially >75 years) without causing symptoms 4
• May be positive in older FTD patients or those with apolipoprotein ε4 genotype 1
• Negative amyloid PET effectively excludes AD, which is diagnostically valuable 1

FDG-PET shows abnormalities earlier than structural imaging:

• Metabolic changes precede atrophy visible on CT/MRI
• In preclinical AD, amyloid PET is positive in areas where FDG-PET metabolism remains normal 1
• This temporal sequence makes PET essential for early detection and intervention

For Your Specific Patient

Given the advanced clinical presentation (hypersomnia, poor oral intake suggesting severe disease), both FDG-PET and amyloid PET would provide:

• Confirmation of AD pathology for family counseling and prognosis
• Assessment of whether disease-modifying therapy eligibility exists (though likely too advanced)
• Exclusion of treatable alternative diagnoses
• Baseline for monitoring if any intervention attempted

CT would only confirm what is already clinically obvious (advanced brain atrophy) without providing actionable diagnostic, prognostic, or therapeutic guidance.